Compare Ascendis Pharma A/S (ASND) vs Dicks Sporting Goods Inc (DKS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Dicks Sporting Goods Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Dicks Sporting Goods Inc trades at $217.98 (market cap $19.51B). The key difference: Ascendis Pharma A/S and Dicks Sporting Goods Inc are close in size by market cap, and Dicks Sporting Goods Inc pays a 2.29% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | DKS | |
|---|---|---|
Market Cap | $17.74B | $19.51B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $239.17 |
52-Week Low | $163.32 | $187.78 |
Enterprise Value | $18.11B | $26.30B |
Dividend Yield | — | 2.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
DKS trades at $217.98, up 0.3% on the day, with a bearish technical signal but strong fundamentals including a 6% comps growth in Q1 2026 and three consecutive quarterly earnings beats. Recent developments include the launch of the ScoreCard+ loyalty program and a partnership with Lids to expand fan merchandise in over 100 stores by late summer 2026. The stock shows robust profitability with a 20.9% ROE and a 4.71% net income margin, supported by $1.17B net income in 2025.
The outlook is positive with a consensus price target of $261, representing 19.7% upside, and no sell ratings among 64 analysts. Key risks include ongoing shareholder litigation over fiduciary duties and competitive pressures in sporting goods retail. The stock presents a growth opportunity driven by strategic expansions and consistent earnings performance, though investors should monitor legal developments and market share sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →
